Surgery Doctors in Haddon Heights, NJ Accepting Medicare

8 Surgery doctors found. Showing 1 - 8

Dr. Lawrence Edward Greenawald, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 120 White Horse Pike Ste 103, Haddon Heights, NJ 08035 Phone: 856-546-3900

Margaret Merriam, MARGARET MERRIAM DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 120 White Horse Pike, Suite 103, Haddon Heights, NJ 08035 Phone: 856-546-3900    Fax: 856-546-9308

David Adam Berg, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 120 White Horse Pike, Suite 103, Haddon Heights, NJ 08035 Phone: 856-546-3900    Fax: 856-546-3908

Dr. Jamaal H Shaban, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 120 White Horse Pike Ste 103b, Haddon Heights, NJ 08035 Phone: 856-546-3900

Dr. Rodrigo R Santos, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 17 White Horse Pike Ste 6, Haddon Heights, NJ 08035 Phone: 856-547-5522    Fax: 856-547-0416

Dr. Brendan Mccracken, M.D. Surgery - Surgical Critical Care Medicare: Accepting Medicare Assignments Practice Location: 120 White Horse Pike Ste 103b, Haddon Heights, NJ 08035 Phone: 856-546-3900

Brian Charles Smeal, MD FACS Surgery Medicare: Medicare Enrolled Practice Location: 120 White Horse Pike, Suite 103, Haddon Heights, NJ 08035 Phone: 856-546-3900    Fax: 856-546-3908

Mr. Alan Roy Swiecicki, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1000 Kings Highway, Haddon Heights, NJ 08035 Phone: 856-546-9023    Fax: 856-546-9825

News Archive

Making public policies on vaccination with limited information

"Let's say you're a public health official from the Centers for Disease Control, and you don't really know how much disease is going to be averted by vaccinating different fractions of the population," said Manski, the Board of Trustees Professor in Economics in the Weinberg College of Arts and Sciences. "Then how should you choose a policy? That's really what the paper tries to address."

Savient fourth quarter net loss increases to $30.9 million

Savient Pharmaceuticals, Inc. reported financial results for the three months ended December 31, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA(pegloticase). Savient ended the quarter with approximately $170 million in cash and short-term investments, a decrease of $33 million for the quarter.

Australian clinical trial of potent new anticancer drug (CYT997)

Up to 30 patients with advanced incurable solid-tumours are to be involved in clinical trials of a potent new anticancer drug (CYT997), developed by Australian biotechnology company, Cytopia Limited.

Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems

Expectant mothers may be able to prevent potentially serious medical problems in themselves and their babies simply by boosting their daily calcium intake, says a new systematic review.

Read more Medical News

› Verified 9 days ago